

HOLLIS EDEN PHARMACEUTICALS INC /DE/  
Form 8-K  
May 31, 2005

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): May 31, 2005

---

**HOLLIS-EDEN PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

---

**Delaware**

(State or other jurisdiction of incorporation)

**000-24672**  
(Commission File No.)

**13-3697002**  
(IRS Employer Identification No.)

Edgar Filing: HOLLIS EDEN PHARMACEUTICALS INC /DE/ - Form 8-K

4435 Eastgate Mall, Suite 400

San Diego, California 92121

(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: (858) 587-9333

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**ITEM 8.01. OTHER EVENTS.**

On May 31, 2005, Hollis-Eden Pharmaceuticals, Inc., a Delaware corporation (the Company), issued a press release announcing that on May 31, 2005, the Company filed with the U.S. Food and Drug Administration an Investigational New Drug application for its drug candidate NEUMUNE (HE2100). See Exhibit 99.1 for the text of the press release.

**ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.**

**EXHIBITS.**

99.1 Press release issued on May 31, 2005 by Hollis-Eden Pharmaceuticals, Inc.

2.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**HOLLIS-EDEN PHARMACEUTICALS, INC.**

Dated: May 31, 2005

By: /s/ Eric J. Loumeau

---

Eric J. Loumeau  
Vice President, General Counsel

3.

**INDEX TO EXHIBITS**

99.1 Press Release issued on May 31, 2005 by Hollis-Eden Pharmaceuticals, Inc.

4.